A Phase 3 interventional study of Arimoclomol in Inclusion Body Myositis, sponsored by ZevraDenmark. Terminated at 12 sites in 2 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.
Sponsored by ZevraDenmark · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 in phase 3, and was the 26th registered.
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
Browse Myositis, Inclusion Body studies →4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Myositis International Health & Research Collaborative Alliance Foundation · Sites in United States
Ages 7+
Austin Neuromuscular Center · Sites in United States
Ages 45–75
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 2–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 9
First in 1990; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.
Median enrollment 24 across the 27 interventional studies, 59 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 37 have an industry lead sponsor. The 10 most frequent:
ZevraDenmark is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
ZevraDenmark has 2 studies filed under Myositis, Inclusion Body — fewer than ten, so there is no comparison to draw.
2 of the studies in Myositis, Inclusion Body with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05046821University of California, IrvineSporadic Inclusion Body Myositis Natural History Study | 2027-03-31 |
| NCT06479863Austin Neuromuscular CenterEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)
This was planned to be a 40-month open-label extension trial of the 20-month randomized, double-blind, placebo-controlled IBM4809 trial. The open-label trial was terminated early by the sponsor as a consequence of the results of IBM4809 which did not meet any of its efficacy endpoints. Therefore, the actual average duration of open-label treatment was approximately 28 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for female participants until 4 weeks after last dose and for male participants up to 3 months after last dose. Premenopausal women must have a negative pregnancy test prior to dosing with trial medication. Acceptable methods of birth control are:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
Drug: Arimoclomol
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score
The Inclusion Body Myositis Functional Rating Scale (IBMFRS) includes 10 measures (swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs), each graded on a Likert scale from 0 (being unable to perform) to 4 (normal). The sum of the 10 items gives a value between 0 and 40. A higher score represents less functional limitation. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Change in Six Minutes Walking Distance Test; Distance at 6 Minutes (6MWD)
Patients were instructed to walk down one side of a track and back along the opposite side as quickly and safely as possible for 6 minutes. Patients were allowed to take breaks as needed during the walking period, but timing continued during breaks. The distance walked in meters was recorded after 6 minutes. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Change in Modified Timed Up and Go (mTUG)
The Modified Timed Up and Go (mTUG) measures the patient's ability to get up from a chair (allowing patients to use their arms), walk 3 meters, turn around, walk back to the chair, and sit down. The use of nearby walls or assistance from a caregiver was not allowed. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Change in Quadriceps Muscle Strength
Maximal voluntary isometric contraction testing (MVICT) of the patient's quadriceps muscle (extensor strength of the knee) were performed using a hand myometer which is a hand-held device that allows the examiner to push against a muscle while the patient resists. The test was performed on each side. The results for the stronger knee are reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Change in Hand Grip Strength
Hand grip strength was assessed using a dynamometer. The test was performed on each hand. The grip strength of the stronger hand is reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Change in the 36-Item Short Form Health Survey (SF-36)
The 36-Item Short Form Health Survey (SF-36) is a 36-item, patient-reported survey of health status. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No derived scores were calculated for SF-36 and no summary tabulation was done.
Time frame: Change from Baseline in IBM-OLE to Early Termination Visit
Number of Falls and Near Falls
Patients recorded the number of falls and near falls in a falls diary. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No tabulation of falls and near falls was performed.
Time frame: Baseline to Early Termination Visit
| Milestone | Arimoclomol (Open-label) |
|---|---|
| Started | 121 |
| Completed | 0 |
| Not completed | 121 |
| Withdrew: Adverse event | 18 |
| Withdrew: Death | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Other | 1 |
| Withdrew: The trial was terminated early by the sponsor | 86 |
The Inclusion Body Myositis Functional Rating Scale (IBMFRS) includes 10 measures (swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs), each graded on a Likert scale from 0 (being unable to perform) to 4 (normal). The sum of the 10 items gives a value between 0 and 40. A higher score represents less functional limitation. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
| score on a scale | Arimoclomol (Open-label) |
|---|---|
| Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score | -1.7 ± 2.60 |
Patients were instructed to walk down one side of a track and back along the opposite side as quickly and safely as possible for 6 minutes. Patients were allowed to take breaks as needed during the walking period, but timing continued during breaks. The distance walked in meters was recorded after 6 minutes. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
| meters | Arimoclomol (Open-label) |
|---|---|
| Change in Six Minutes Walking Distance Test; Distance at 6 Minutes (6MWD) | -17.2 ± 61.06 |
The Modified Timed Up and Go (mTUG) measures the patient's ability to get up from a chair (allowing patients to use their arms), walk 3 meters, turn around, walk back to the chair, and sit down. The use of nearby walls or assistance from a caregiver was not allowed. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
| meters/second | Arimoclomol (Open-label) |
|---|---|
| Change in Modified Timed Up and Go (mTUG) | -0.027 ± 0.0847 |
Maximal voluntary isometric contraction testing (MVICT) of the patient's quadriceps muscle (extensor strength of the knee) were performed using a hand myometer which is a hand-held device that allows the examiner to push against a muscle while the patient resists. The test was performed on each side. The results for the stronger knee are reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
| kg | Arimoclomol (Open-label) |
|---|---|
| Change in Quadriceps Muscle Strength | -0.48 ± 3.719 |
Hand grip strength was assessed using a dynamometer. The test was performed on each hand. The grip strength of the stronger hand is reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.
| kg | Arimoclomol (Open-label) |
|---|---|
| Change in Hand Grip Strength | -0.23 ± 4.616 |
The 36-Item Short Form Health Survey (SF-36) is a 36-item, patient-reported survey of health status. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No derived scores were calculated for SF-36 and no summary tabulation was done.
No measurements were reported for this outcome.
Patients recorded the number of falls and near falls in a falls diary. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No tabulation of falls and near falls was performed.
No measurements were reported for this outcome.
Collected over Adverse events (AEs) were collected from the first dose of study medication until 14 days following the latest administration of study medication. AEs were assessed monthly for the first 6 months, and then every second or third month. The time frame for collection of AEs was from Baseline in IBM-OLE to Early Termination (variable, an average of approximately 28 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arimoclomol (Open-label) | 2/121 (1.7%) | 13/121 (10.7%) | 97/121 (80.2%) |
| Event | Arimoclomol (Open-label) |
|---|---|
| Corona virus infectionInfections and infestations | 2/121 |
| Transaminases increasedInvestigations | 2/121 |
| PneumoniaInfections and infestations | 1/121 |
| Electrocardiogram abnormalInvestigations | 1/121 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 |
| Crohn's diseaseGastrointestinal disorders | 1/121 |
| Large intestine perforationGastrointestinal disorders | 1/121 |
| Disease progressionGeneral disorders | 1/121 |
| Event | Arimoclomol (Open-label) |
|---|---|
| ConstipationGastrointestinal disorders | 15/121 |
| Alanine aminotransferase increasedInvestigations | 14/121 |
| Aspartate aminotransferase increasedInvestigations | 13/121 |
| DiarrhoeaGastrointestinal disorders | 13/121 |
| Transaminases increasedInvestigations | 10/121 |
| Gamma-glutamyltransferase increasedInvestigations | 10/121 |
| InsomniaPsychiatric disorders | 9/121 |
| NauseaGastrointestinal disorders | 8/121 |
| ContusionInjury, poisoning and procedural complications | 7/121 |
| Blood lactate dehydrogenase increasedInvestigations | 7/121 |
Safety population: All patients who received at least 1 dose or partial dose of arimoclomol in IBM-OLE.
| Age, Continuous(years) | Arimoclomol (Open-label) |
|---|---|
| Mean | 66.2 ± 7.91 |
| Sex: Female, Male(Participants) | Arimoclomol (Open-label) |
|---|---|
| Female | 23 |
| Male | 98 |
| Race/Ethnicity, Customized(Participants) | Arimoclomol (Open-label) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Black or African American | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 115 |
| Other | 2 |
| Multiple | 0 |
| Age at diagnosis(years) | Arimoclomol (Open-label) |
|---|---|
| Mean | 62.3 ± 8.02 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in Nov 2021, 29 months.
Results were first posted in Sep 2023, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arimoclomol
ZevraDenmark